Myoview (Tetrofosmin)

Tetrofosmin is labeled with technetium‑99m and acts as a lipophilic cation. After intravenous injection it rapidly crosses cell membranes and accumulates in myocardial cells in proportion to the local blood flow, allowing gamma‑camera detection of perfusion patterns.

The administered activity of Myoview is determined by the prescribing physician based on patient weight, the imaging protocol, and the specifications of the SPECT equipment. The product is supplied as a kit for reconstitution and is given as a single intravenous injection.

Safety data for Myoview in pregnancy and lactation are limited. It should only be used when the potential diagnostic benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician after careful risk‑benefit assessment.

To order Myoview, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Myoview (tetrofosmin) and technetium‑99m sestamibi have comparable diagnostic performance. Tetrofosmin offers rapid myocardial uptake and relatively fast clearance, which can shorten imaging time, whereas sestamibi may show slightly higher liver uptake. Choice of agent often depends on local protocol preferences and availability.

Myoview must be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. The reconstituted solution should be used promptly according to the product’s stability guidelines and handled only by trained personnel.

Myoview is provided as a sterile injectable solution kit for reconstitution. After preparation, the radiopharmaceutical is administered intravenously, typically as a single bolus injection, followed by a waiting period before image acquisition as defined by the specific SPECT protocol.

Serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and radiation‑induced skin injury at the injection site. Patients should be monitored during and after injection, and any signs of a severe reaction should be managed immediately according to emergency guidelines.

Myoview is contraindicated in patients with known hypersensitivity to tetrofosmin or any component of the formulation. It should also be used with caution or avoided in individuals with severe renal impairment, uncontrolled thyroid disorders, or those who are pregnant or breastfeeding unless the diagnostic benefit clearly outweighs the risk.